​Linda Pissott Reig, shareholder in the firm's FDA & Biotechnology section, comments on the impact of a company citing attorney-client privilege in a dispute with the FDA.

“This raises an interesting issue. The company has a lawful right to claim privilege to certain information, but it also raises questions about whether the company is being fully forthcoming,” said Linda Pissott Reig at the Buchanan Ingersoll & Rooney law firm, where she handles FDA and compliance issues. “It’s unclear whether there was enough transparency in the discussions with the company to know if (asserting) privilege was appropriate or too broad.”

Read more in "Can a Small Drug Maker Make Amends with the FDA After Giving its Inspectors the Bum’s Rush?" in STAT News.